Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T04:37:57Z', 'timestamp': 1711600677178}, 'reference-count': 31, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 6, 1]], 'date-time': '2021-06-01T00:00:00Z', 'timestamp': 1622505600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 6, 1]], 'date-time': '2021-06-01T00:00:00Z', 'timestamp': 1622505600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-017'}, { 'start': { 'date-parts': [[2021, 6, 1]], 'date-time': '2021-06-01T00:00:00Z', 'timestamp': 1622505600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-037'}, { 'start': { 'date-parts': [[2021, 6, 1]], 'date-time': '2021-06-01T00:00:00Z', 'timestamp': 1622505600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-012'}, { 'start': { 'date-parts': [[2021, 6, 1]], 'date-time': '2021-06-01T00:00:00Z', 'timestamp': 1622505600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-029'}, { 'start': { 'date-parts': [[2021, 6, 1]], 'date-time': '2021-06-01T00:00:00Z', 'timestamp': 1622505600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-004'}], 'funder': [ { 'DOI': '10.13039/501100005849', 'name': 'Baqiyatallah University of Medical Sciences', 'doi-asserted-by': 'publisher', 'award': ['IRCT20200318046812N1']}, { 'DOI': '10.13039/100012021', 'name': 'Iran University of Medical Sciences', 'doi-asserted-by': 'publisher', 'award': ['IRCT20200318046812N1']}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 6]]}, 'DOI': '10.1016/j.intimp.2021.107522', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 12]], 'date-time': '2021-03-12T10:23:15Z', 'timestamp': 1615544595000}, 'page': '107522', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 45, 'title': 'Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia', 'prefix': '10.1016', 'volume': '95', 'author': [ {'given': 'Masoud', 'family': 'Solaymani-Dodaran', 'sequence': 'first', 'affiliation': []}, {'given': 'Mostafa', 'family': 'Ghanei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehdi', 'family': 'Bagheri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Qazvini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ensieh', 'family': 'Vahedi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Seyed', 'family': 'Hassan Saadat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Seyed', 'family': 'Amin Setarehdan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Akram', 'family': 'Ansarifar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hossein', 'family': 'Biganeh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arash', 'family': 'Mohazzab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Davood', 'family': 'Khalili', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amir', 'family': 'Hosein Ghazale', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Reza Heidari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Taheri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maliheh', 'family': 'Khoramdad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Mahdi Asadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Masoud', 'family': 'Nazemieh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mojtaba', 'family': 'Varshochi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samaneh', 'family': 'Abbasian', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Bakhtiari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Reza', 'family': 'Mosaed', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Seyyed-Javad', 'family': 'Hosseini-shokouh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Masoume', 'family': 'Shahrokhi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zeynab', 'family': 'Yassin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Ali Zohal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maryam', 'family': 'Qaraati', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nafiseh', 'family': 'Rastgoo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ramin', 'family': 'Sami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Javad Eslami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Akram', 'family': 'Asghari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mansoor', 'family': 'Namazi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shadi', 'family': 'Ziaie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raana', 'family': 'Jafari-Moghaddam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saeid', 'family': 'Kalantari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Memarian', 'sequence': 'additional', 'affiliation': []}, {'given': 'Javad', 'family': 'Khodadadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Hossein Afshari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mansooreh', 'family': 'Momen-Heravi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Niusha', 'family': 'Behzadseresht', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmad', 'family': 'Reza Mobayen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abolfazl', 'family': 'Mozafari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fatemeh', 'family': 'Movasaghi', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Maryam', 'family': 'Haddadzadeh Shoushtari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Javad', 'family': 'Moazen', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '3', 'key': '10.1016/j.intimp.2021.107522_b0005', 'doi-asserted-by': 'crossref', 'first-page': '100', 'DOI': '10.1016/j.cmrp.2020.05.013', 'article-title': 'Literature-based review of the drugs used for the treatment of COVID-19', 'volume': '10', 'author': 'Venkatasubbaiah', 'year': '2020', 'journal-title': 'Curr Med Res Pract'}, { 'issue': 'SI-1', 'key': '10.1016/j.intimp.2021.107522_b0010', 'first-page': '611', 'article-title': 'Antiviral treatment of COVID-19. Turk', 'volume': '50', 'author': 'Şimşek Yavuz', 'year': '2020', 'journal-title': 'J Med Sci'}, { 'key': '10.1016/j.intimp.2021.107522_b0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s40264-020-00965-w', 'article-title': 'The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: ' 'Implications for Pharmacovigilance', 'author': 'Tuccori', 'year': '2020', 'journal-title': 'Drug Safety'}, { 'issue': '4', 'key': '10.1016/j.intimp.2021.107522_b0020', 'doi-asserted-by': 'crossref', 'first-page': '977', 'DOI': '10.1128/AAC.46.4.977-981.2002', 'article-title': 'In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705', 'volume': '46', 'author': 'Furuta', 'year': '2002', 'journal-title': 'Antimicrobial Agents and Chemotherapy'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.107522_b0025', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'volume': '93', 'author': 'Furuta', 'year': '2017', 'journal-title': 'Proceedings of the Japan Academy Series B, Physical and biological ' 'sciences'}, { 'key': '10.1016/j.intimp.2021.107522_b0030', 'doi-asserted-by': 'crossref', 'unstructured': 'Shannon A, Selisko B, Le N, et al. Favipiravir strikes the SARS-CoV-2 at ' 'its Achilles heel, the RNA polymerase. bioRxiv 2020: 2020.05.15.098731.', 'DOI': '10.1101/2020.05.15.098731'}, { 'key': '10.1016/j.intimp.2021.107522_b0035', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/cpt.1844', 'article-title': 'Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for ' '2019-nCoV Infection', 'author': 'Du', 'year': '2020', 'journal-title': 'Clinical pharmacology and therapeutics'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.107522_b0040', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pmed.1001967', 'article-title': 'Experimental Treatment with Favipiravir for Ebola Virus Disease (the ' 'JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept ' 'Trial in Guinea', 'volume': '13', 'author': 'Sissoko', 'year': '2016', 'journal-title': 'PLoS medicine'}, { 'issue': '18', 'key': '10.1016/j.intimp.2021.107522_b0045', 'first-page': '1824', 'article-title': 'Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A ' 'Review', 'volume': '323', 'author': 'Sanders', 'year': '2020', 'journal-title': 'Jama'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.107522_b0050', 'doi-asserted-by': 'crossref', 'first-page': '1454', 'DOI': '10.1016/j.mayocp.2020.04.027', 'article-title': 'Treatment Considerations for COVID-19: A Critical Review of the ' 'Evidence (or Lack Thereof)', 'volume': '95', 'author': 'Vijayvargiya', 'year': '2020', 'journal-title': 'Mayo Clinic proceedings'}, { 'key': '10.1016/j.intimp.2021.107522_b0055', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.intimp.2020.107228', 'article-title': 'Therapeutic drugs for SARS-CoV-2 treatment: Current state and ' 'perspective', 'volume': '90', 'author': 'Bolarin', 'year': '2021', 'journal-title': 'International Immunopharmacology'}, { 'key': '10.1016/j.intimp.2021.107522_b0060', 'doi-asserted-by': 'crossref', 'first-page': '107232-', 'DOI': '10.1016/j.intimp.2020.107232', 'article-title': 'A comparative analysis for anti-viral drugs: Their efficiency against ' 'SARS-CoV-2', 'volume': '90', 'author': 'Kivrak', 'year': '2021', 'journal-title': 'International immunopharmacology'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.107522_b0065', 'doi-asserted-by': 'crossref', 'first-page': '4', 'DOI': '10.1186/s40779-020-0233-6', 'article-title': 'A rapid advice guideline for the diagnosis and treatment of 2019 novel ' 'coronavirus (2019-nCoV) infected pneumonia (standard version)', 'volume': '7', 'author': 'Jin', 'year': '2020', 'journal-title': 'Military Medical Research'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.107522_b0070', 'article-title': 'Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of ' 'Current Evidence, Guideline Recommendations, and Perspectives. Journal ' 'of', 'volume': '9', 'author': 'Meini', 'year': '2020', 'journal-title': 'Clinical Medicine'}, { 'key': '10.1016/j.intimp.2021.107522_b0075', 'unstructured': 'Scientific Bureau of National COVID-19 Management Committee. Iranian ' 'National Guideline for dignosis and treatment of COVID-19. MOHME, ' 'Ministry of Health and Medical Education 2020. p. 13-4.'}, { 'issue': '19', 'key': '10.1016/j.intimp.2021.107522_b0080', 'doi-asserted-by': 'crossref', 'first-page': '1787', 'DOI': '10.1056/NEJMoa2001282', 'article-title': 'A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe ' 'Covid-19', 'volume': '382', 'author': 'Cao', 'year': '2020', 'journal-title': 'The New England journal of medicine'}, { 'key': '10.1016/j.intimp.2021.107522_b0085', 'article-title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus ' 'disease 2019: open label, randomised controlled trial', 'volume': '369', 'author': 'Tang', 'year': '2020', 'journal-title': 'BMJ (Clinical research ed)'}, { 'issue': '25', 'key': '10.1016/j.intimp.2021.107522_b0090', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational Study of Hydroxychloroquine in Hospitalized Patients with ' 'Covid-19', 'volume': '382', 'author': 'Geleris', 'year': '2020', 'journal-title': 'New England Journal of Medicine'}, { 'key': '10.1016/j.intimp.2021.107522_b0095', 'first-page': '1', 'author': 'Moschini', 'year': '2020', 'journal-title': 'Effects on QT interval of hydroxychloroquine associated with ' 'ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 ' 'infection.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.107522_b0100', 'doi-asserted-by': 'crossref', 'first-page': '84-', 'DOI': '10.1038/s41392-020-0191-1', 'article-title': 'Immune response in COVID-19: addressing a pharmacological challenge by ' 'targeting pathways triggered by SARS-CoV-2', 'volume': '5', 'author': 'Catanzaro', 'year': '2020', 'journal-title': 'Signal Transduct Target Ther'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.107522_b0105', 'doi-asserted-by': 'crossref', 'first-page': '405', 'DOI': '10.1016/j.healun.2020.03.012', 'article-title': 'COVID-19 illness in native and immunosuppressed states: A ' 'clinical-therapeutic staging proposal', 'volume': '39', 'author': 'Siddiqi', 'year': '2020', 'journal-title': 'J Heart Lung Transplant'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.107522_b0110', 'doi-asserted-by': 'crossref', 'first-page': '128', 'DOI': '10.1111/joim.13063', 'article-title': 'Early antiviral treatment contributes to alleviate the severity and ' 'improve the prognosis of patients with novel coronavirus disease ' '(COVID-19)', 'volume': '288', 'author': 'Wu', 'year': '2020', 'journal-title': 'J Intern Med'}, { 'issue': '4', 'key': '10.1016/j.intimp.2021.107522_b0115', 'doi-asserted-by': 'crossref', 'first-page': '2000607', 'DOI': '10.1183/13993003.00607-2020', 'article-title': 'Pathogenesis of COVID-19 from a cell biology perspective', 'volume': '55', 'author': 'Mason', 'year': '2020', 'journal-title': 'European Respiratory Journal'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.107522_b0120', 'doi-asserted-by': 'crossref', 'DOI': '10.7189/jogh.10.010377', 'article-title': 'Can early treatment of patients with risk factors contribute to ' 'managing the COVID-19 pandemic?', 'volume': '10', 'author': 'Giammaria', 'year': '2020', 'journal-title': 'Journal of global health'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.107522_b0125', 'doi-asserted-by': 'crossref', 'first-page': '578-', 'DOI': '10.1186/s13054-020-03288-5', 'article-title': 'Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA ' 'clearance: a case series', 'volume': '24', 'author': 'Fu', 'year': '2020', 'journal-title': 'Crit Care'}, { 'key': '10.1016/j.intimp.2021.107522_b0130', 'doi-asserted-by': 'crossref', 'unstructured': 'McCullough PA. Favipiravir and the Need for Early Ambulatory Treatment ' 'of SARS-CoV2 Infection (COVID-19). Antimicrobial Agents and Chemotherapy ' '2020: AAC.02017-20.', 'DOI': '10.1128/AAC.02017-20'}, { 'key': '10.1016/j.intimp.2021.107522_b0135', 'first-page': '1', 'article-title': 'Efficacy of favipiravir in COVID-19 treatment: a multi-center ' 'randomized study', 'author': 'Dabbous', 'year': '2021', 'journal-title': 'Arch Virol'}, { 'key': '10.1016/j.intimp.2021.107522_b0140', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.01897-20', 'article-title': 'A prospective, randomized, open-label trial of early versus late ' 'favipiravir in hospitalized patients with COVID-19', 'author': 'Doi', 'year': '2020', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '10.1016/j.intimp.2021.107522_b0145', 'doi-asserted-by': 'crossref', 'unstructured': 'Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for ' 'COVID-19: An Open-Label Control Study. Engineering (Beijing, China) ' '2020.', 'DOI': '10.1016/j.eng.2020.03.007'}, { 'key': '10.1016/j.intimp.2021.107522_b0150', 'doi-asserted-by': 'crossref', 'unstructured': 'Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment ' 'of Patients with Moderate COVID-19: Interim Results of a Phase II/III ' 'Multicenter Randomized Clinical Trial. Clinical infectious diseases : an ' 'official publication of the Infectious Diseases Society of America 2020.', 'DOI': '10.1093/cid/ciaa1176'}, { 'key': '10.1016/j.intimp.2021.107522_b0155', 'unstructured': 'Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary ' 'Report. New England Journal of Medicine 2020.'}], 'container-title': 'International Immunopharmacology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1567576921001582?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1567576921001582?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 4, 15]], 'date-time': '2023-04-15T09:09:37Z', 'timestamp': 1681549777000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1567576921001582'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 6]]}, 'references-count': 31, 'alternative-id': ['S1567576921001582'], 'URL': 'http://dx.doi.org/10.1016/j.intimp.2021.107522', 'relation': {}, 'ISSN': ['1567-5769'], 'subject': ['Pharmacology', 'Immunology', 'Immunology and Allergy'], 'container-title-short': 'International Immunopharmacology', 'published': {'date-parts': [[2021, 6]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Immunopharmacology', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.intimp.2021.107522', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 Elsevier B.V. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '107522'}